返回 Agendas
Real-World Use of Multi-Criteria Decision Analysis for Benefit-Risk Assessment: Lessons Learned in the Industrial Setting
Session Chair(s)
Kevin Marsh, PhD, MSc
Vice President, Patient-Centered Research
Evidera, United Kingdom
There is increased demand for quantitative benefit-risk assessment (BRA). Various reviews have recommended multi-criteria decision analysis (MCDA) to undertake quantitative BRA (e.g., PROTECT). The objective of this session is learn from real examples of conducting MCDA for BRA in an industry setting.
Learning Objective : Explain the scientific basis for the uses of multi-criteria decision analysis (MCDA); Discuss MCDA in the context of real world application within benefit-risk assessments in industry settings; Identify the strengths and weaknesses/limitations of MCDA.
Speaker(s)
MCDA in the Benefit-Risk Evaluation of Medicines: What Sponsor and Health Agency Applications and Perspectives Have Taught Us So Far
Filip Mussen, PhD
Janssen R&D, Pharmaceutical Companies of Johnson & Johnson, Belgium
Vice President, Regional Regulatory Affairs
Best Practice in MCDA: An Illustrated Summary of Best Practice Guidelines
Kevin Marsh, PhD, MSc
Evidera, United Kingdom
Vice President, Patient-Centered Research
注册方法
Registration override should work.